Shear-induced platelet aggregation is important in physiological hemostasis and in the pathogenesis of arterial thrombosis. It requires extracellular Ca 2+ , platelet membrane glycoproteins Ib/IX and Ilb/IIIa, von Willebrand factor (vWF), and ADP. We studied the effects of desmopressin (DDAVP), which increases plasma vWF levels and shortens the bleeding time, and of ticlopidine, which inhibits platelet responses to ADP, on shear-induced platelet aggregation. Eleven healthy volunteers were given oral ticlopidine (250 mg b.i.d.) for 7 days. The same subjects were infused intravenously with DDAVP (03 jug/kg body wt) before the first and after the last doses of ticlopidine. The degree of platelet aggregation induced by shear stress at 25, 50, 75, and 100 dyne/cm 2 in a cone-and-plate viscometer, plasma vWF levels, and the bleeding time were measured before and after each DDAVP infusion. Plasma vWF levels and the extent of shear-induced platelet aggregation increased after DDAVP and were correlated. Ticlopidine partially inhibited shearinduced platelet aggregation both before and after DDAVP infusion. The bleeding time, prolonged by ticlopidine, was shortened by DDAVP. Potentiation by DDAVP of shear-induced platelet aggregation may be one mechanism by which the drug shortens the prolonged bleeding time. Since shear-induced platelet aggregation can cause thrombotic occlusions in stenotic arterial vessels, our findings may explain the therapeutic efficacy of ticlopidine in arterial thrombosis. (Arteriosclerosis and Thrombosis 1993;13:393-397) 
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Since the rheological conditions that can be found in the normal microcirculation or at sites of severe arterial stenosis are characterized by high shear, 23 pharmacological modulation of platelet aggregation at high shear may be clinically relevant. Potentiation might improve primary hemostasis but heighten the risk of thrombus formation in stenotic arteries, whereas inhibition might impair primary hemostasis but reduce the risk of arterial thrombosis. Inhibitors of shear-induced platelet aggregation are substances that interfere with the binding of vWF to GP Ib/IX or GP Ilb/IIIa complexes 18 -2224 and prostaglandins that increase platelet cyclic adenosine monophosphate. 25 Partial inhibition can be accomplished with ADP scavengers, suggesting that the ADP released from platelets contributes to the formation of shearinduced platelet aggregates.
- 26 In contrast, drugs that interfere with the platelet cyclooxygenase pathway, such as acetylsalicylic acid, have no inhibitory effects. 21 -27 In this study, the effects on shear-induced platelet aggregation of two commonly used drugs that affect the hemostatic system, ticlopidine and desmopressin (DDAVP), were tested. Ticlopidine is an antiaggregating agent with antithrombotic effects, 28 which selectively inhibits platelet responses to ADP 2930 and prolongs the bleeding time. DDAVP, a synthetic analogue of vasopressin, increases the plasma levels of vWF and factor VIII and shortens the bleeding times of normal individuals and patients with congenital and acquired defects of primary hemostasis.
31
Methods
Materials
]creatinine sulfate, 57.5 mCi/nmol) was obtained from Amersham International (Buckinghamshire, UK). ADP, the endoperoxide analogue 9-epoxymethanoprostaglandin F 2a U46619, collagen, and Triton X-100 were purchased from Sigma Chemical Co., St. Louis, Mo. All chemicals were of reagent grade or better. DDAVP (Minirin DDAVP) was from Valeas, Milano, Italy, and ticlopidine (Ticlid) from Sanofi-Winthrop, Milano, Italy.
Treatment Protocol
Eleven healthy volunteers (six women, five men; aged 27-36 years) were given oral ticlopidine (250 mg b.i.d.) for 7 days. DDAVP (0.3 Mg/kg body wt) was infused intravenously over 30 minutes before the first and after the last dose of ticlopidine.
Before and 5 minutes after each infusion of DDAVP, the bleeding time was measured (Symplate II, Organon Teknika, Milan, Italy), and blood was taken from an antecubital vein and anticoagulated with 12.9 mmol/L trisodium citrate.
Shear-Induced Platelet Aggregation
Blood samples were centrifuged at ISOg at room temperature for 10 minutes to obtain platelet-rich plasma (PRP). The platelet count in the PRP was adjusted to 3xl0"/L with autologous platelet-poor plasma (PPP), obtained by centrifugation of blood at l,200g for 15 minutes.
Duplicate PRP samples (350 /iL) were exposed to controlled shear stress levels (25, 50, 75 , and 100 dyne/cm 2 ) in a stainless steel cone-and-plate viscometer (Controlled Stress Rheometer, Carri-med, Dorking, UK) at 37°C for 45 seconds. The cone diameter was 6 cm and its angle 0.21°; the distance between the cone and the plate was adjusted with an electronic sensor. After being subjected to shear stress, 25 /iL of PRP was added to 100 uh of 2.5% paraformaldehyde in phosphate-buffered saline, and the number of single platelets per microliter was counted under a phase-contrast light microscope. The appearance of platelet aggregates was accompanied by a decrease in the number of single platelets. Thus, the percent increase in platelet aggregation was directly related to the percent decrease in platelet count. Results were expressed as a percentage of single platelet counts of PRP incubated in the cone-and-plate viscometer at 37°C for 45 seconds without shearing.
Platelet Lysis
To determine the extent of platelet lysis caused by shear forces, 150 ;u,L of the PRP remaining on the plate of the viscometer was centrifuged in an Eppendorf microcentrifuge for 2 minutes to obtain PPP, in which the concentration of lactate dehydrogenase (LDH) was determined with a commercial kit (LDH opt, Boehringer, Mannheim, FRG). The results were expressed as percent of LDH concentration in 1% Triton X-100 lysates of PRP, after subtraction of the concentration present in the PPP of unsheared samples.
Platelet Aggregation and Release Reaction Measured in the Light-Transmission Aggregometer
Twenty milliliters of blood was collected in 12.9 mmol/L trisodium citrate on the first day of treatment (before the administration of ticlopidine), before and after the infusion of DDAVP. Platelet aggregation and release of [ 
Analysis of Plasma von Willebrand Factor
Measurement of plasma vWF antigen (vWF: Ag) and of the ristocetin cofactor activity (vWF:RiCof) levels and the multimeric analysis of vWF were performed as previously described, 32 using an electroimmunoassay (for v\VF:Ag), an aggregometric assay with formalinfixed platelets (for vWF:RiCof), and low-resolution, sodium dodecyl sulfate-agarose gel electrophoresis (for vWF multimers).
Statistical Analysis
Results are expressed as mean±SEM. Differences among groups were analyzed using one-way analysis of variance, followed by the Student-Newman-Keuls test when appropriate.
Results
Shear-Induced Platelet Aggregation
Exposure of PRP to increasing controlled shear stresses for 45 seconds caused a progressive reduction in the number of single platelets per microliter (Figure 1) , which was associated with the appearance of platelet aggregates. In all experiments, the percentage of platelet lysis, calculated as percent increase in plasma LDH concentrations, was always less than 5% and, therefore, the reduction in platelet count after shearing can be attributed mostly to the formation of platelet aggregates. Platelet aggregation did not occur at a shear stress of 25 progressively increased to about 40% at a shear stress of 100 dyne/cm 2 . The infusion of DDAVP caused a doubling of plasma vWF:Ag and vWF:RiCof levels (Table 1 ) and the appearance of supranormal vWF multimers (Figure 2 ). After DDAVP, shear-induced platelet aggregation increased ( Figure 1) : it was already detectable (approximately 20%) after exposure of PRP to a shear stress level of 50 dyne/cm 2 and increased to about 60% at a shear stress of 100 dyne/cm 2 . A shear stress of 75 dyne/cm 2 after DDAVP induced the same degree of platelet aggregation induced by 100 dyne/cm 2 before DDAVP.
Ticlopidine partially inhibited platelet aggregation induced by shear stress (Figure 1 ). The inhibition was statistically significant at levels of shear stress of 75 and 100 dyne/cm 2 (/J<0.01). The aggregation of ticlopidinetreated platelets after the infusion of DDAVP was comparable to that of untreated platelets before the infusion of DDAVP (Figure 1 ). Ticlopidine had no effects on either the increases in plasma vWF:Ag and vWF:RiCof levels (Table 1) or the appearance of vWF with supranormal multimers (Figure 2 ) caused by DDAVP.
Platelet aggregation induced by a shear stress of 100 dyne/cm 2 under basal conditions and after DDAVP administration was positively correlated with the plasma levels of vWF:Ag (/-=0.50,/7<0.001).
Bleeding Time
DDAVP significantly shortened the bleeding times of the 11 healthy volunteers at both baseline and after the prolongation induced by oral ticlopidine ( Table 2) .
Effects of Desmopressin on Platelet Aggregation and Release of [ I4 C]Serotonin Induced by Platelet Agonists
The administration of DDAVP did not significantly affect the extent of platelet aggregation (Table 3) 
Discussion
The results of this study indicate that the degree of shear-induced platelet aggregation is correlated with plasma vWF levels and is potentiated by the infusion of DDAVP, which increases plasma vWF levels by inducing the release of vWF with supranormal multimers from endothelial cells. These ex vivo findings are consistent with the demonstration that vWF plays a key role in shear-induced platelet aggregation 1822 and that su- pranormal vWF multimers derived from human endothelial cells grown in vitro are more effective than the largest multimers normally present in plasma. 18 The increase in plasma vWF levels induced by DDAVP explains the normalization of the bleeding time in patients with defects of vWF. 31 However, DDAVP shortens the bleeding times not only of patients with von Willebrand disease, but also of normal subjects and of patients with congenital or acquired defects of primary hemostasis who have normal plasma vWF levels. 31 Although mechanisms independent of released vWF are certainly operative, 32 it has been suggested that the effect of the drug might also be mediated by the increase in plasma vWF that it induces. 31 This study supports this hypothesis, since it shows that DDAVP potentiates the aggregation of normal and abnormal (ticlopidine-treated) platelets that occurs at levels of shear that can be found in the microcirculation and, therefore, are relevant to bleeding time measurements. The increased aggregation occurring at high shear stress after DDAVP is probably the result only of the induced increase in plasma vWF concentrations and the appearance of supranormal vWF multimers, since platelet reactivity to aggregating stimuli is not affected by DDAVP, as shown by our light-transmission aggregometer studies.
Recent reports have cautioned against the use of DDAVP for individuals with evidence of coronary and/or cerebral atherosclerosis, since it may precipitate acute myocardial infarction or ischemic stroke. 33 - 34 This study elucidates the pathophysiology of such severe clinical complications. Shear stress increases abruptly to very high levels at sites of severe arterial stenosis and may therefore cause platelet aggregation. Evidence for this mainly comes from in vivo studies performed with the experimental model described by Folts et al, 35 in which the induction of severe stenosis in canine coronary arteries caused a cyclic reduction of coronary blood flow due to the cyclic formation of platelet aggregates and their spontaneous deaggregation. Experiments in swine with severe von Willebrand disease and arterial stenosis have shown that the severe deficiency of vWF in these animals protects them from the cyclic reduction of arterial blood flow and the develop- ment of occlusive thrombosis. 36 " 38 Hence, since the vWF-dependent aggregation at high shear plays such an important pathogenetic role in acute arterial occlusions, its potentiation by DDAVP might increase the risk of myocardial infarction and ischemic stroke in atherosclerotic patients.
In the same way, the pharmacological inhibition of shear-induced platelet aggregation should reduce the risk of arterial thrombosis. Only in vitro studies have been performed so far, and they showed that molecules that interfere with the interaction of vWF with the platelet GP Ib/IX or GP Ilb/IIIa complexes completely inhibited shear-induced platelet aggregation. These included monoclonal antibodies against vWF, GP Ib/IX, or GP Ilb/IIIa 18 -22 and aurintricarboxylic acid, 24 which inhibits the interaction of vWF with GP Ib/IX. Shearinduced platelet aggregation is also effectively inhibited in vitro by prostaglandins that increase the platelet cyclic adenosine monophosphate levels, such as prostacyclin. 25 Among the antiaggregating drugs that are commonly used in clinical practice, only acetylsalicylic acid has been tested in vitro, and it was found to be ineffective. 21 ' 27 In our ex vivo study we found that ticlopidine, an antiaggregating drug with proven antithrombotic effects, partially inhibited shear-induced platelet aggregation under basal conditions and after its potentiation by DDAVP. This is consistent with the demonstration that shear-induced platelet aggregation is partially due to released ADP, 21 -26 since ticlopidine selectively inhibits the platelet responses to ADP. 29 -30 In conclusion, this is the first ex vivo study showing that shear-induced platelet aggregation can be modulated in normal subjects by drugs that interfere with the hemostatic system. Modulation of shear-induced platelet aggregation may be useful both for the treatment of patients with hemorrhagic disorders and for the management of patients at risk for arterial thrombosis.
